If you shop for a weight-loss drug online, you are not looking at one market. You are looking at four or five different business models wearing similar landing pages. The category you buy from shapes what you actually get: which product, at what price, from a clinician licensed where, and with what recourse when something goes wrong.
This is a map of the players by type, not a ranking or an endorsement. Naming a company as an example of a model is not a judgment about that company.
Large direct-to-consumer platforms
The most visible players are independent DTC telehealth companies — Hims & Hers, Ro, LifeMD, and weight-focused apps like Noom among them. The model is a subscription: you complete an online intake, a clinician (ideally licensed in your state) reviews it, and if appropriate a prescription goes to a pharmacy. The company’s revenue is the recurring membership, not just the drug.
Their menus vary and change often. Some carry branded, FDA-approved GLP-1s; some have sold compounded versions; some bundle coaching, labs, or oral kits. The legitimacy question here is less “is telehealth prescribing real” — it is — and more whether this platform does a meaningful clinical evaluation and is transparent about total cost. For how a sound prescribing process should look, see How online GLP-1 prescribing actually works.
Manufacturer-direct channels
A newer category is the drugmakers selling to patients themselves. Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare are cash-pay programs that dispense only that company’s own branded, FDA-approved products, frequently routing the clinical visit through partnered telehealth providers. Both have also struck deals letting outside platforms sell their branded drugs at set self-pay prices.
The trade-off is straightforward: a narrow menu (one company’s drugs) in exchange for a shorter, verifiable supply chain — you are buying the real, approved product from its maker. Prices are set by the manufacturer and shift over time, so treat any specific figure you see as a snapshot, not a fixed rate. These programs also generally exclude patients using Medicare or Medicaid.
Compounding-focused sellers
During the 2022–2025 GLP-1 shortages, federal law let pharmacies compound copies of drugs in short supply, and a wave of low-cost telehealth sellers built their pricing around compounded semaglutide and tirzepatide. That window is closing. The FDA has stated the shortages are resolved and clarified enforcement timelines for compounders, and has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk. The FDA notes that compounded drugs do not undergo the agency’s premarket review for safety, effectiveness, and quality. A site still leading with cheap “compounded” GLP-1s in 2026 warrants extra scrutiny about what exactly it is dispensing and under what legal basis.
Insurer- and employer-linked telehealth
A quieter category runs through coverage rather than cash. Established telehealth firms such as Teladoc, and platforms embedded in health plans or employer benefits, connect members to prescribers with the drug billed through insurance. Access here is gated by your plan’s formulary and prior-authorization rules rather than by a subscription checkout — often cheaper if covered, often unavailable if not.
How the models differ on legitimacy
Across all four, the same fundamentals define a legitimate provider: a clinician actually licensed in your state (the Federation of State Medical Boards tracks how telemedicine rules vary), a licensed dispensing pharmacy, and honest disclosure of the full cost and cancellation terms before you pay.
That last point is not hypothetical. In December 2025 the FTC finalized an order against telehealth weight-loss seller NextMed over allegations of undisclosed costs, deceptive weight-loss claims, distorted reviews, and cancellation practices designed to trap subscribers. The lesson: the model being widespread does not make any single seller trustworthy. Judge the provider, not the category.
This article is not medical advice, and we make no efficacy or safety claims about any drug or seller. For our checklist on spotting a bad actor, see Red flags at online weight-loss clinics.